Zacks Analyst Blog Highlights: Roche Holding AG, Anthem, Inc. and Infosys Limited

0

For immediate release

Chicago, IL – January 20, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Roche Holding AG RHHBY, Anthem, Inc. ANTM and Infosys Limited INFY.

Here are highlights from Wednesday’s analyst blog:

Main research reports for Roche, Anthem and Infosys

Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHBY), Anthem, Inc. (ANTM) and Infosys Limited (INFI). These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.

You can see all today’s research reports here >>>

Shares of rock have slightly underperformed the industry Zacks Large Cap Pharmaceuticals over the past year (+12.8% vs. +17.5%), however, things seem to be looking up for it. The Zacks analyst believes the strong growth of Ocrevus, Evrysdi, Tecentriq and Hemlibra is helping Roche counter biosimilar competition for several of its traditional drugs. Another major positive is the approval of new drugs.

Roche’s Diagnostics segment is expected to continue to show strong performance with new launches over the coming year. The division is poised to benefit from strong demand for COVID-19 testing as well as other diagnostic platforms. RHHBY’s performance over the year was encouraging, with the core pharmaceuticals business showing signs of recovery.

(You can read the full Roche research report here >>>)

Anthem shares have gained +15.6% over the past six months against the industry Zacks Medical Health Maintenance Organization’s +9.4% gain. The Zacks analyst believes strategic buyouts and collaborations, improved revenue, and an expanded product portfolio are likely to drive Anthem’s long-term growth.

Acquisitions and collaborations have enabled ANTM to boost its Medicare Advantage growth and also to strengthen its business portfolio. The momentum in Medicare and Medicaid business, coupled with contract wins, is expected to boost Anthem enrollment. However, escalating costs and a weak balance sheet continue to weigh on its margins and have an impact on its financial flexibility.

(You can read the full Anthem research report here >>>)

Shares of Infosys have gained +6.5% in the last three months compared to a loss of -16.6% for Zacks IT services sector. The Zacks analyst believes that Infosys has benefited greatly from the conclusion of major contracts as well as the momentum in digital services.

INFY’s continued focus on Agile Digital and AI-enabled core services is a tailwind. Strong demand for its cloud, Internet of Things, cybersecurity, data and analytics services is a key driver. However, steadily rising anti-outsourcing sentiments in some parts of the world, rising contractor costs and revised Infosys compensation weighed on margins.

(You can read the full Infosys research report here >>>)

Other noteworthy reports we’re featuring today include Norfolk Southern Corp. (NSC) and Chipotle Mexican Grill, Inc. (GCM).

7 best stocks for the next 30 days

Just Released: Experts distill 7 elite stocks from the current Zacks No. 1 Ranking 220 Strong Buys list. They consider these tickers “most likely for early price increases.”

Since 1988, the full list has beaten the market more than 2 times with an average gain of +25.3% per year. So be sure to give your immediate attention to these 7 handpicked ones.

Discover them now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

https://www.zacks.com

Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.

Zacks names ‘only one best choice for doubling up’

From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.

As one investor put it, “curing and preventing hundreds of diseases…what should this market be worth?” This company could rival or surpass other recent Zacks stocks that are expected to double, such as Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in a year.

Free: See our best stock and our 4 finalists >>

Click to get this free report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Share.

Comments are closed.